Baseline | Randomization | Treatment phase (start within 4 weeks after randomization) | |||||
---|---|---|---|---|---|---|---|
Treatment Arm | Arm A (8–17 weeks) | Arm B (6–11 weeks) | |||||
Postoperative Visit | Intermediate Visiti | Final Visit | Intermediate Visiti | Final Visit | |||
Study week (W) | −4 | 0 | 1–4 | 9–13 | 12–17 | 3–7 | 6–11 |
Informed consentb(Study and translational research) | -4 | ||||||
Medical history incl. smoking and alcohol, demographics | X | ||||||
Eligibility criteriaa | X | ||||||
CT or MRI Neck | X | ||||||
CT Chest/Abdomen | X | ||||||
Physical examinationb | −2 | X | X | X | X | X | |
Performance status/ASA | −2 | X | X | X | X | X | |
Vital signsc | −2 | X | X | X | X | X | |
Laboratory determinationsd | X | X | X | X | X | X | |
Panendoscopy, FFPE tissuea | X | Xe | |||||
Audiometry | X | X | X | ||||
Blood draw translat. researcha | X | X | Xj | X | Xj | X | |
Dental evaluation and panoramic view as indicated | X | ||||||
Postoperative morbiditya | X | X | X | X | |||
Swallowing functiona f | X | X | X | X | X | X | |
Nutritional evaluation | X | ||||||
Quality of life assessmenta g | X | X | X | X | X | X | |
Health Care Utilization and Productivity lossa h | X | ||||||
Monitoring AE’s/SAE’sa | X (Randomization to 28 days after the last administration of IMP and/or 5 months after randomization in this trial) | ||||||
Survival | X |